PedroPiedraMD
Pediatric Infectious Disease • Houston, TXProfessor, Virology & Microbiology, Baylor College of Medicine
Dr. Piedra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1504 Taub Loop
Houston, TX 77030Phone+1 713-873-5437Fax+1 713-873-4337
Education & Training
University at BuffaloFellowship, Pediatric Infectious Diseases, 1984 - 1987
Medical University of South CarolinaResidency, Pediatrics, 1981 - 1984
University of South Florida College of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1988 - 2025
SC State Medical License 1982 - 1984- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Fellow (FAAP) American Academy of Pediatrics
Publications & Presentations
PubMed
- 311 citationsSARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.Jing Hui Tian, Nita Patel, Robert Haupt, Haixia Zhou, Stuart Weston
Nature Communications. 2021-01-14 - 237 citationsCirculation Patterns of Group A and B Human Respiratory Syncytial Virus Genotypes in 5 Communities in North AmericaTeresa C. T. Peret, Caroline B. Hall, Gregory W. Hammond, Pedro A. Piedra, Gregory A. Storch
The Journal of Infectious Diseases. 2000-06-01 - 180 citationsGeneration and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus InfectionLaurent Detalle, Thomas Stohr, Concepción Palomo, Pedro A. Piedra, Brian E. Gilbert
Antimicrobial Agents and Chemotherapy. 2016-01-01
Other
- Respiratory Syncytial Virus Fusion Nanoparticle Vaccine Immune Responses Target Multiple Neutralizing Epitopes That Contribute to Protection Against Wild-Type and Pali...Pedro Piedra, MD, ScienceDirect
https://www.doximity.com/articles/ec82b951-b191-4406-8038-7129da66ac6c
UpToDate, Wolters Kluwer Health - 2013-03-13 - Respiratory Syncytial Virus Fusion Nanoparticle Vaccine Immune Responses Target Multiple Neutralizing Epitopes That Contribute to Protection Against Wild-Type and Pali...Pedro Piedra, MD, ScienceDirect
https://www.doximity.com/articles/ec82b951-b191-4406-8038-7129da66ac6c
UpToDate, Wolters Kluwer Health - 2013-01-09
Press Mentions
FluMist: Who Is the Nasal Spray Best For?October 22nd, 2024- COVID, Flu and RSV: Know the Vaccines for These Three Common Respiratory VirusesSeptember 4th, 2024
- Why the Summer Olympic Games in Paris May Have Been a COVID 'Success' StoryAugust 15th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
